CONTINUING EDUCATION (CE) LANGUAGE

Title:                   Emerging Therapeutic Frontiers in Pediatric IBD: IL-23 Blockade, JAK Inhibitors and Subcutaneous Biologics

Date:                   February 25, 2026

Location:             Online

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). NASPGHAN is accredited by the ACCME to provide continuing medical education for physicians.

ACCME provider number: 0005000

Credit Designation Statement

NASPGHAN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

ABP MOC Part 2 Credits

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn up to 1.5 MOC Part 2 points for the live webinar in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

Participant must complete the assessment within 30 days of the activity.

As therapeutic options for pediatric inflammatory bowel disease (IBD) rapidly evolve, clinicians must stay current on the next generation of therapies that have the potential to dramatically enhance patient outcomes and quality of life.

Emerging Therapeutic Frontiers in Pediatric IBD brings you an interactive, case-driven webinar that will delve into three groundbreaking areas transforming pediatric IBD care: IL-23 Blockade, JAK Inhibitors and Subcutaneous Biologic Medications. 

Expert faculty will guide attendees through mechanisms of action, clinical trial outcomes, real-world evidence, and safety considerations, offering up-to-date insights that bridge cutting-edge research and everyday practice. By the end of this webinar, participants will be equipped with practical strategies to integrate these novel therapies into comprehensive treatment plans, optimize disease monitoring, and collaborate effectively with multidisciplinary teams, ultimately advancing care for children living with IBD.